142 related articles for article (PubMed ID: 31870649)
1. Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility.
Burmistrov V; Morisseau C; D'yachenko V; Karlov D; Butov GM; Hammock BD
Bioorg Med Chem Lett; 2020 Feb; 30(3):126908. PubMed ID: 31870649
[TBL] [Abstract][Full Text] [Related]
2. Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors.
Burmistrov V; Morisseau C; Karlov D; Pitushkin D; Vernigora A; Rasskazova E; Butov GM; Hammock BD
Bioorg Med Chem Lett; 2020 Sep; 30(18):127430. PubMed ID: 32736212
[TBL] [Abstract][Full Text] [Related]
3. 1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors.
Burmistrov V; Morisseau C; Danilov D; Harris TR; Dalinger I; Vatsadze I; Shkineva T; Butov GM; Hammock BD
Bioorg Med Chem Lett; 2015 Dec; 25(23):5514-9. PubMed ID: 26520661
[TBL] [Abstract][Full Text] [Related]
4. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S
Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357
[TBL] [Abstract][Full Text] [Related]
5. Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.
Burmistrov V; Morisseau C; Lee KS; Shihadih DS; Harris TR; Butov GM; Hammock BD
Bioorg Med Chem Lett; 2014 May; 24(9):2193-7. PubMed ID: 24685540
[TBL] [Abstract][Full Text] [Related]
6. 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
Codony S; Pujol E; Pizarro J; Feixas F; Valverde E; Loza MI; Brea JM; Saez E; Oyarzabal J; Pineda-Lucena A; Pérez B; Pérez C; Rodríguez-Franco MI; Leiva R; Osuna S; Morisseau C; Hammock BD; Vázquez-Carrera M; Vázquez S
J Med Chem; 2020 Sep; 63(17):9237-9257. PubMed ID: 32787085
[No Abstract] [Full Text] [Related]
7. Adamantyl thioureas as soluble epoxide hydrolase inhibitors.
Burmistrov V; Morisseau C; Pitushkin D; Karlov D; Fayzullin RR; Butov GM; Hammock BD
Bioorg Med Chem Lett; 2018 Jul; 28(13):2302-2313. PubMed ID: 29803731
[TBL] [Abstract][Full Text] [Related]
8. Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
Du F; Sun W; Morisseau C; Hammock BD; Bao X; Liu Q; Wang C; Zhang T; Yang H; Zhou J; Xiao W; Liu Z; Chen G
Eur J Med Chem; 2021 Nov; 223():113678. PubMed ID: 34218083
[TBL] [Abstract][Full Text] [Related]
9. Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability.
Burmistrov V; Morisseau C; Harris TR; Butov G; Hammock BD
Bioorg Chem; 2018 Feb; 76():510-527. PubMed ID: 29310082
[TBL] [Abstract][Full Text] [Related]
10. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Kim IH; Heirtzler FR; Morisseau C; Nishi K; Tsai HJ; Hammock BD
J Med Chem; 2005 May; 48(10):3621-9. PubMed ID: 15887969
[TBL] [Abstract][Full Text] [Related]
11. Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase.
Chen H; Zhang Y; Ye C; Feng TT; Han JG
J Biomol Struct Dyn; 2014; 32(8):1231-47. PubMed ID: 23815795
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.
Kim IH; Lee IH; Nishiwaki H; Hammock BD; Nishi K
Bioorg Med Chem; 2014 Feb; 22(3):1163-75. PubMed ID: 24433964
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs).
Das N; Dhanawat M; Kulshrestha A; Shrivastava SK
Med Chem; 2011 Nov; 7(6):581-92. PubMed ID: 22313298
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of amide-phosphonate derivatives as inhibitors of the human soluble epoxide hydrolase.
Kim IH; Park YK; Nishiwaki H; Hammock BD; Nishi K
Bioorg Med Chem; 2015 Nov; 23(22):7199-210. PubMed ID: 26507430
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain.
Lee KSS; Ng JC; Yang J; Hwang SH; Morisseau C; Wagner K; Hammock BD
Bioorg Med Chem; 2020 Nov; 28(22):115735. PubMed ID: 33007552
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors.
Takai K; Chiyo N; Nakajima T; Nariai T; Ishikawa C; Nakatani S; Ikeno A; Yamamoto S; Sone T
Bioorg Med Chem Lett; 2015 Apr; 25(8):1705-1708. PubMed ID: 25800114
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.
Karami L; Saboury AA; Rezaee E; Tabatabai SA
Eur Biophys J; 2017 Jul; 46(5):445-459. PubMed ID: 27928588
[TBL] [Abstract][Full Text] [Related]
18. Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors.
Hwang SH; Morisseau C; Do Z; Hammock BD
Bioorg Med Chem Lett; 2006 Nov; 16(22):5773-7. PubMed ID: 16949285
[TBL] [Abstract][Full Text] [Related]
19. The 5-substituted piperazine as a novel secondary pharmacophore greatly improving the physical properties of urea-based inhibitors of soluble epoxide hydrolase.
Li HY; Jin Y; Morisseau C; Hammock BD; Long YQ
Bioorg Med Chem; 2006 Oct; 14(19):6586-92. PubMed ID: 16784862
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent Soluble Epoxide Hydrolase (sEH) Inhibitors by Pharmacophore-Based Virtual Screening.
Waltenberger B; Garscha U; Temml V; Liers J; Werz O; Schuster D; Stuppner H
J Chem Inf Model; 2016 Apr; 56(4):747-62. PubMed ID: 26882208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
